The earnings call reflects significant progress in revenue and FDA approvals, alongside challenges in trial enrollment and operational delays. The company remains optimistic about future opportunities in both pediatric and adult markets.

Company Guidance

During the SeaStar Medical first quarter 2025 financial results call, the company provided several key metrics and guidance. They achieved a fourfold increase in revenue compared to the fourth quarter of 2024, reaching $293,000, primarily driven by increased adoption of their QUELIMMUNE therapy. The NEUTRALIZE-AKI trial for adult acute kidney injury (AKI) reached a 50% enrollment milestone, with expectations to complete enrollment by year-end 2025. The market opportunity for adult AKI is estimated at $4.5 billion annually in the U.S., based on approximately 200,000 adult patients. SeaStar Medical is also pursuing breakthrough device designations for additional indications and aims to file a premarket approval (PMA) application for adult AKI in 2026. Their strategy includes expanding their customer base, with six pediatric sites commercially active and more in the pipeline. The company is also focused on maintaining fiscal discipline, reporting a reduced net loss of $3.7 million in Q1 2025, compared to $12.7 million in Q1 2024.

Significant Revenue Growth

SeaStar Medical reported a fourfold increase in first-quarter revenue compared to the fourth quarter of 2024, driven by the increased adoption of QUELIMMUNE therapy.

FDA Breakthrough Device Designations

The company received two new breakthrough device designations from the FDA for their SCD therapy, expanding their pipeline indications to address hyperinflammation during adult and pediatric cardiac surgery.

NEUTRALIZE-AKI Trial Progress

The NEUTRALIZE-AKI trial for adult patients reached a 50% enrollment milestone, triggering an interim analysis by the Data Safety Monitoring Board.

Pediatric Market Expansion

QUELIMMUNE therapy has been adopted by multiple new nationally recognized children's hospitals, indicating growing market penetration.

Strong Market Potential for Adult AKI

The adult AKI market presents a $4.5 billion annual opportunity, with plans to file a PMA in 2026.

SeaStar Medical Holding (ICU) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ICU Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.15 / -	-1.1	―	―	―
Aug 13, 2025	2025 (Q2)	-0.43 / -0.18	-1.03	82.52% (+0.85)	―
May 14, 2025	2025 (Q1)	-0.52 / -0.44	-4.75	90.74% (+4.31)	―
Mar 27, 2025	2024 (Q4)	-0.89 / -0.90	-4.75	81.05% (+3.85)	―
Nov 13, 2024	2024 (Q3)	-1.13 / -1.10	-9.25	88.11% (+8.15)	―	―
Aug 13, 2024	2024 (Q2)	-1.41 / -1.03	-6.25	83.52% (+5.22)	―	―
May 14, 2024	2024 (Q1)	- / -	-10	―	―	―
Apr 17, 2024	2023 (Q4)	- / -4.75	-10	52.50% (+5.25)	―	―
Nov 14, 2023	2023 (Q3)	-6.25 / -9.25	-1.188	-678.62% (-8.06)	―	―
Aug 14, 2023	2023 (Q2)	-6.25 / -6.25	0.35	-1885.71% (-6.60)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ICU Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.73	$0.88	+20.55%
May 14, 2025	$1.23	$1.24	+0.81%
Mar 27, 2025	$2.20	$1.70	-22.73%
Nov 13, 2024	$2.52	$1.96	-22.22%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does SeaStar Medical Holding (ICU) report earnings?

SeaStar Medical Holding (ICU) is schdueled to report earning on Nov 12, 2025, After Close (Confirmed).

What is SeaStar Medical Holding (ICU) earnings time?

SeaStar Medical Holding (ICU) earnings time is at Nov 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ICU EPS forecast?

ICU EPS forecast for the fiscal quarter 2025 (Q3) is -0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing